SEC Tracker
Get the app

Hims & Hers Health HIMS

Hims & Hers Health Q1 FY25: revenue $586.0M, up 111%; diluted EPS $0.20

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.3
Material contract

Key figures from this report

These are the numbers Hims & Hers Health reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$586.0M+111% from $278.2M in Q1 FY2410-Q income statement, on EDGAR
  2. Net income$49.5M+345% from $11.1M in Q1 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.20+300% from $0.05 in Q1 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$273.7M+160% from $105.2M in Q1 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$109.1M+322% from $25.8M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Hims & Hers Health files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8011 and related industry codes: the same peer list as the financial tables.

  1. Teladoc Health TDOC public float $1.5B, Jun 30, 2025
  2. LifeMD LFMD public float $512M, Jun 30, 2025
  3. Starling Oncology TOI public float $137M, Jun 30, 2025
  4. Airsculpt Technologies AIRS public float $80M, Jun 30, 2025
  5. SBC Medical Group Holdings SBC public float $48M, Jun 30, 2025